What Is Cerebrolysin? Benefits, Research & Safety
A multi-peptide neuroprotective preparation derived from porcine brain tissue, approved in some countries for stroke recovery and neurodegenerative conditions.
UK summary: Not a licensed UK medicine. A multi-peptide preparation from porcine brain tissue, licensed in several European and Asian countries for stroke recovery, dementia, and TBI. Substantial regional clinical literature, much from Russian / Chinese groups; not on UK NHS pathways.
Quick Facts
Overview
Cerebrolysin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. A multi-peptide preparation from porcine brain tissue, licensed in several European and Asian countries for stroke recovery, dementia, and TBI. Substantial regional clinical literature, much from Russian / Chinese groups; not on UK NHS pathways.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not approved by the MHRA. Not available through standard UK prescribing.
- EU: Approved in several EU member states (Austria, Germany, and others) for neurological indications.
- Notes: Approved in over 40 countries worldwide. Not approved by the FDA or MHRA. Available on prescription in approved countries.
05Approved medical uses
- Stroke recovery (licensed in several European, Asian, and Latin American countries; NOT MHRA-licensed in the UK).
- Alzheimer's disease and vascular dementia (licensed in some jurisdictions; NOT in the UK).
- Traumatic brain injury rehabilitation (licensed in some jurisdictions; NOT in the UK).
06Unapproved / promotional claims
- Reverses Alzheimer's disease.
- Cures stroke damage if started early.
- Boosts cognition in healthy adults for exam prep or high-stakes work.
- Safe to self-administer at home as IV or IM infusion.
07Common internet claims
- Marketed by private 'neuroregeneration' clinics for off-label cognitive enhancement.
- Sold by online retailers as research-only injectable.
- Promoted in nootropic stacks alongside Semax and Selank.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Recovers function after stroke” | C | Yes | Moderate | Licensed in many jurisdictions with positive trial data; UK guidelines do not include Cerebrolysin. |
| “Treats Alzheimer's” | C | Limited | Moderate | Some trials report cognitive benefits; not a UK-licensed Alzheimer's treatment. |
| “Boosts cognition in healthy adults” | E | No | High | No evidence for healthy-adult cognitive enhancement. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Injection-site reactions; fever, sweating, dizziness reported.
- Theoretical risk from porcine-brain-derived preparation (BSE-class concerns historically reviewed).
- Hypersensitivity reactions possible.
- Sterility and prion-screening of grey-market vials unverified.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Not approved by the MHRA. Not available through standard UK prescribing.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Approved in several EU member states (Austria, Germany, and others) for neurological indications.
15What this page cannot tell you
- Whether a UK-purchased vial is genuine Cerebrolysin from the licensed manufacturer.
- Whether IV/IM technique used outside a clinic is sterile.
- What outcome benefit (if any) applies to your specific neurological condition.
- Whether the Russian/Chinese trial evidence base would meet UK NICE quality thresholds.
16Last reviewed
17Citation quality score
18Research gaps
- No UK NICE technology appraisal supports Cerebrolysin for any indication.
- Western Phase 3 trial replication of stroke / dementia benefits limited.
- Healthy-adult cognitive-outcome data absent.
- Long-term safety in non-licensed jurisdictions unstudied.
19Safer alternatives / established care pathways
- NHS stroke pathway with evidence-based rehabilitation (physio, OT, SLT).
- NHS memory clinic for cognitive concerns and licensed Alzheimer's medications.
- NHS TBI rehabilitation pathway for traumatic brain injury.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Cerebrolysin a licensed UK medicine?
- What UK-approved treatments exist for the neurological condition I'm asking about?
- Is there an NHS specialist pathway for my situation?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Neuroprotection against excitotoxicity, oxidative stress, and apoptosis
- 2Enhancement of neuroplasticity and synaptic function
- 3Support for functional recovery after ischaemic stroke
- 4Potential cognitive improvement in Alzheimer's disease
- 5Promotion of neurogenesis from neural stem cells
- 6Improved outcomes in traumatic brain injury models
Claim vs Evidence
How popular claims about Cerebrolysin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Recovers function after stroke” | C | Yes | Moderate | Licensed in many jurisdictions with positive trial data; UK guidelines do not include Cerebrolysin. |
| “Treats Alzheimer's” | C | Limited | Moderate | Some trials report cognitive benefits; not a UK-licensed Alzheimer's treatment. |
| “Boosts cognition in healthy adults” | E | No | High | No evidence for healthy-adult cognitive enhancement. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Clinical protocols use 10-30 mL IV daily for acute neurological conditions; 5-10 mL for chronic conditions |
| Frequency | Daily IV infusion for 10-21 day treatment cycles |
| Duration | Typical cycles of 10-21 days, repeated as clinically indicated |
| Notes | Administered by intravenous infusion in clinical settings. Not suitable for self-administration. Dosing determined by treating physician based on indication and severity. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous infusion
- Intramuscular injection (lower doses)
| Half-Life | Stability |
|---|---|
| Complex pharmacokinetics due to multi-peptide composition; clinical effects observed during and after treatment cycles | Supplied as a ready-to-use aqueous solution. Store at room temperature protected from light. |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Dizziness
- Headache
- Injection site reactions
- Agitation (rare)
- Mild gastrointestinal symptoms
Rare Risks & Concerns
- Allergic reactions
- Seizures in predisposed individuals (rare)
Contraindications
- Epilepsy
- Severe renal impairment
- Known hypersensitivity to porcine-derived products
- Pregnancy and breastfeeding
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved by the MHRA. Not available through standard UK prescribing.
🇪🇺 European Union
Approved in several EU member states (Austria, Germany, and others) for neurological indications.
Clinical Studies Summary
CASTA Trial — Cerebrolysin in Acute Ischaemic Stroke
A large randomised controlled trial of 1,070 acute ischaemic stroke patients comparing Cerebrolysin 30 mL/day to placebo for 10 days. While the primary endpoint showed trends toward improvement, predefined responder analysis showed significantly better outcomes in the Cerebrolysin group.
Cerebrolysin in Alzheimer's Disease
Multiple randomised controlled trials have evaluated Cerebrolysin in mild-to-moderate Alzheimer's disease. A Cochrane review found evidence of benefit on global clinical impression measures, though cognitive benefits were inconsistent across studies.
Cerebrolysin in Traumatic Brain Injury
Clinical studies suggest Cerebrolysin may improve functional outcomes after traumatic brain injury. The CAPTAIN trial demonstrated improved cognitive recovery in TBI patients receiving Cerebrolysin compared to placebo.
Looking for Cerebrolysin?
Source research-grade Cerebrolysin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Cerebrolysin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Cerebrolysin a licensed UK medicine?
- What UK-approved treatments exist for the neurological condition I'm asking about?
- Is there an NHS specialist pathway for my situation?
UK regulatory & safety context
Related Research Guides
Related Peptides
Selank
A synthetic peptide based on tuftsin, developed in Russia for anxiolytic and nootropic properties, approved there for anxiety and neurasthenia.
Learn moreSemax
A synthetic peptide based on ACTH, developed in Russia as a nootropic and neuroprotectant, approved there for cognitive disorders and stroke.
Learn moreDSIP
A neuropeptide originally isolated for its sleep-inducing properties, now researched for stress protection, pain modulation, and metabolic effects.
Learn moreBDNF
A critical growth factor for brain health, neuroplasticity, and neuronal survival, with implications for depression, memory, and neurodegenerative diseases.
Learn more